Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant
Public ClinicalTrials.gov record NCT00044733. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Dose-Finding Study of the Safety of Gemtuzumab Ozogamicin as Single Agent Treatment of Patients With Relapsed Acute Myelogenous Leukemia After Autologous or Allogenic Hematopoietic Stem Cell Transplant (HSCT)
Study identification
- NCT ID
- NCT00044733
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Enrollment
- 38 participants
Conditions and interventions
Conditions
Interventions
- Mylotarg (gemtuzumab ozogamicin) Injection Drug
Drug
Eligibility (public fields only)
- Age range
- 0 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 29, 2000
- Primary completion
- Not listed
- Completion
- Aug 31, 2004
- Last update posted
- May 17, 2006
2000 – 2004
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Little Rock | Arkansas | 72211 | — |
| Not listed | Hartford | Connecticut | 06102 | — |
| Not listed | Jacksonville | Florida | 32209 | — |
| Not listed | Honolulu | Hawaii | 96813 | — |
| Not listed | Olathe | Kansas | 66061 | — |
| Not listed | Camden | New Jersey | 08103 | — |
| Not listed | Trenton | New Jersey | 08629 | — |
| Not listed | Buffalo | New York | 14215 | — |
| Not listed | Rochester | New York | 14642 | — |
| Not listed | Canton | Ohio | 44708 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | Charleston | West Virginia | 25304 | — |
| Not listed | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00044733, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 17, 2006 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00044733 live on ClinicalTrials.gov.